Substance Use Disorder Treatment: Options and Resources

Substance use disorder (SUD) affects an estimated 48.7 million Americans age 12 and older, according to the 2023 National Survey on Drug Use and Health (NSDUH) published by the Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment exists across a wide spectrum — from same-day crisis stabilization to years-long outpatient support — and the match between a person's clinical needs and the right level of care makes a measurable difference in outcomes. This page maps the treatment landscape: what SUD treatment actually is, how the clinical process works, and what distinguishes one type of program from another.

Definition and scope

Substance use disorder is a clinical diagnosis defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a pattern of substance use that causes significant impairment or distress, meeting at least 2 of 11 specific criteria within a 12-month period (American Psychiatric Association, DSM-5). Those criteria span tolerance, withdrawal, loss of control, and social consequences — it is not simply a matter of frequency or preference.

The scope of treatable substances includes alcohol, opioids, stimulants (cocaine, methamphetamine), cannabis, sedatives, and hallucinogens, among others. Alcohol use disorder alone accounted for 29.5 million diagnoses in the 2023 NSDUH data — the single largest category.

Treatment is not a single event. SAMHSA and the American Society of Addiction Medicine (ASAM) both frame SUD as a chronic, relapsing condition requiring ongoing management similar in structure to the management of diabetes or hypertension. The national infrastructure for that management spans roughly 17,000 specialized substance use treatment facilities in the United States, as tracked by SAMHSA's National Survey of Substance Abuse Treatment Services (N-SSATS).

The broader healthcare access landscape shapes whether those 17,000 facilities are reachable — cost, geography, and coverage status determine access long before clinical matching begins.

How it works

The clinical pathway for SUD treatment typically follows a structured sequence:

  1. Screening and assessment — A validated tool such as the Alcohol Use Disorders Identification Test (AUDIT) or the Drug Abuse Screening Test (DAST-10) establishes severity. A full ASAM assessment then matches the individual to a level of care.
  2. Medically managed withdrawal (detoxification) — For opioids and alcohol especially, abrupt cessation can be medically dangerous. Detox addresses acute physical dependence and is distinct from treatment itself; SAMHSA explicitly notes that detox alone does not constitute SUD treatment (SAMHSA Treatment Improvement Protocol 45).
  3. Active treatment — The core phase, delivered at intensity levels defined by the ASAM criteria (see below).
  4. Continuing care — Step-down programs, recovery housing, peer support, and mutual aid groups extend the treatment effect over time.

Medications for Addiction Treatment (MAT), also called Medication-Assisted Treatment, are a core evidence-based component for opioid and alcohol use disorders. For opioid use disorder, the FDA has approved three medications: methadone, buprenorphine, and naltrexone (FDA, Information about Medication-Assisted Treatment). For alcohol use disorder, approved medications include naltrexone, acamprosate, and disulfiram. Research consistently shows MAT reduces opioid use, overdose deaths, and criminal activity compared to behavioral treatment alone.

Behavioral therapies — cognitive-behavioral therapy (CBT), contingency management, motivational interviewing — are layered on top of or alongside medication depending on the substance and the individual's needs.

Common scenarios

Opioid use disorder (OUD): A person leaving a hospital after a non-fatal overdose may be initiated on buprenorphine in the emergency department and then connected to an outpatient clinic for ongoing prescribing and counseling. This "bridge prescribing" model has been shown in research published in JAMA Network Open (2019) to significantly increase engagement with formal treatment.

Alcohol use disorder, severe: Inpatient medically supervised detox is typically required before any further treatment. Following stabilization, the clinical picture often points toward a residential program lasting 28 to 90 days, followed by intensive outpatient.

Stimulant use disorder: No FDA-approved medication exists for methamphetamine or cocaine use disorder as of the most recent NIDA treatment research summary. Contingency management — a behavioral therapy using voucher-based incentives — holds the strongest evidence base for stimulants.

Co-occurring mental health conditions: Approximately 21.5 million Americans had co-occurring SUD and mental illness in 2023 (NSDUH 2023). Integrated treatment — addressing both conditions simultaneously rather than sequentially — is the recommended approach, consistent with SAMHSA's TIP 42. Mental health services and SUD treatment increasingly operate under shared clinical frameworks precisely because the populations overlap so substantially.

Decision boundaries

The ASAM Patient Placement Criteria define four broad levels of care, from least to most intensive:

The decision between these levels hinges on six ASAM dimensions: acute intoxication/withdrawal potential, biomedical conditions, emotional/behavioral conditions, readiness to change, relapse potential, and recovery environment. Voluntary insurance coverage requirements under the Mental Health Parity and Addiction Equity Act (MHPAEA) — enforced by CMS and the Department of Labor — legally require that coverage limits for SUD treatment be no more restrictive than those for comparable medical or surgical benefits, though enforcement gaps remain documented by the Government Accountability Office (GAO, GAO-20-150).

References